Bookmarks
Antimicrobial prescribing surveillance data during the COVID-19 pandemic
Population Size
1,602,184
People
Years
2008 - 2021
Associated BioSamples
None/not available
Geographic coverage
United Kingdom
England
Lead time
1-2 months
Summary
Documentation
The use of antimicrobial drugs is linked to antimicrobial resistance which can lead to infections that are harder to treat and may be associated with worse outcomes for the patient.
The use of antibiotics changed in hospital during the different waves of the COVID-19 pandemic, as data was used to assess if antibiotic therapy was associated with better health outcomes for patients with confirmed COVID-19. Looking at changes in health outcomes linked to antibiotic therapy across the whole hospital instead of only patients with COVID-19 over time will help understand if changes to antibiotic use during the pandemic may have had an impact on the risk of antibiotic resistance.
PIONEER geography The West Midlands (WM) has a population of 5.9 million and includes a diverse ethnic and socio-economic mix.
EHR: UHB is one of the largest NHS Trusts in England, providing direct acute services and specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds and an expanded 250 ITU bed capacity during COVID. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary and secondary care record (Your Care Connected) and a patient portal “My Health”.
Scope: Longitudinal and individually linked, so that the preceding and subsequent health journey can be mapped and healthcare utilisation prior to and after admission understood. The dataset includes highly granular patient demographics, co-morbidities taken from ICD-10 and SNOMED-CT codes. Serial, structured data pertaining to process of care (timings, wards and admissions), surgery procedures, microbiology reports, COVID results, prescriptions, drug administered and all outcomes.
Available supplementary data: Matched controls; ambulance, OMOP data, synthetic data.
Available supplementary support: Analytics, Model build, validation and refinement; A.I.; Data partner support for ETL (extract, transform and load) process, Clinical expertise, Patient and end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.
Keywords
Observations
Observed Node | Disambiguating Description | Measured Value | Measured Property | Observation Date |
|---|---|---|---|---|
Persons | 1,602,184 spells between 01.12.2008 and 03.07.2021 | 1602184 | Count | 20 Jan 2022 |
Provenance
Structural Metadata
Details
08/10/2024
20/01/2022
Coverage
01/12/2008
02/07/2021
Accessibility
Data Access Request
Trusted Research Environments (TRE) are built using Microsoft Azure services and hosted in the UK to provide research teams a safe, secure and agile environment which allows users to quickly analyse, interpret and form an enriched view of primary care information through a range of integrated datasets.
Health data collated from multiple sources is ingested into a secure data lake which will then allow subsets of data to be made available to research teams on approval of a data request. Once approved a customer specific TRE is made available with a standard set of leading analytical tools from Microsoft including Azure Databricks, Azure Machine Learning, Azure SQL and Azure Synapse (for large-scale data warehouses). Specific tools can be provided at an additional cost over the standard platform data access charge and the PIONEER team will work with you to determine your exact needs.
Access to the TRE is managed using the latest virtual desktop technology to provide a safe and secure end-user experience. By utilising leading edge design PIONEER are able to create TREs rapidly to enable us to service any customer requirement.